Commission weighs fentanyl‑related enhancements and scope of fentanyl‑related substances
Loading...
Summary
DOJ urged strong, offense‑based enhancements for fentanyl, adulterants (xylazine) and pill presses; defenders and public‑health commentators urged careful targeting, more public‑health input, and worry that some proposed enhancements would be duplicative or lack empirical evidence of reducing harm.
Department of Justice witnesses urged the commission to adopt robust enhancements for fentanyl, fentanyl analogs, and fentanyl‑related substances (FRS), including offense‑based enhancements for distribution to minors, adulterants such as xylazine, pill presses, and dark‑web trafficking. DOJ speakers said these enhancements reflect the exceptional danger of fentanyl and operational challenges for investigators.
Caitlin (DOJ acting narcotics chief) and other DOJ panelists argued some fentanyl threshold decisions should match the HALT Fentanyl Act and that certain enhancements should be offense‑based to avoid mens‑rea hurdles that would substantially limit application.
Defense and public‑health witnesses warned the commission not to adopt broad, undifferentiated FRS treatment without nuanced scientific input. Patricia Richmond and other public‑defense speakers urged the commission to consult addiction researchers, emergency‑room clinicians, and toxicologists before enacting measures that could increase punishment without evidence of public‑health benefit. Several witnesses highlighted uncertainty over the role of xylazine in overdoses and cautioned that naloxone remains a critical treatment step even where xylazine is present.
Some advisory groups supported targeted measures (e.g., pill press enhancements, distribution to minors) but urged narrow drafting to avoid duplication with existing SOCs and to limit litigation and factor‑creep. The commission heard repeated requests for empirical studies and clearer operational definitions before moving forward.
The hearing record shows broad consensus that fentanyl poses extraordinary harms but no consensus on the exact scope, mens‑rea formulation, or applicability of proposed enhancements. The commission signaled it will use submissions and additional expert input to refine any proposed language.
